Printer Friendly

RHeoGene Granted Exclusive License to Stanford University Patents for Ecdysone Receptor Genes.

Business Editors/Health & Medical Writers


CHARLOTTESVILLE, Va.--(BW HealthWire)--June 20, 2001


Advanced Applications Regulate Gene Expression for Cell-Based Assays,

Genomics, Proteomics, Gene Therapy, Cell Culture/Fermentation,

Transgenic Animals, and Biosensors

RHeoGene announced today it has been granted an exclusive license to Stanford University's newly issued U.S. Patent 6,245,531, which covers genes that encode insect-based ecdysone receptors and methods for regulating gene expression in host cells.

The exclusive license joins RHeoGene's current intellectual property estate of more than 45 issued or pending U.S. patents and more than 400 foreign counterparts.

"The Stanford patent significantly strengthens our intellectual property portfolio," said Aris Persidis, Ph.D., managing director of RHeoGene. "It is a critical component of our strategy to develop and commercialize our proprietary, ecdysone-based RHeoSwitch(TM) technology."

RHeoGene's customized RHeoSwitch(TM) systems enable the precise control of both the timing and level of gene expression in a wide variety of host cell types through the interaction of proprietary small molecule RHeoChem(TM) ligand inducers and RHeoCept(TM) receptor proteins. RHeoGene's ecdysone-based RHeoSwitch(TM) inducible gene expression systems turn gene expression on and off, and allow it to be dialed up and down, in a manner analogous to a rheostat control on a light switch.

According to Persidis, RHeoGene will form partnerships to develop and license its RHeoSwitch technology to pharmaceutical and biotechnology partners in each of its core business areas, including drug discovery, functional genomics and proteomics, biotherapeutics production, and novel biosensors.

U.S. Patent 6,245,531 is a continuation of Stanford's Hogness et al. U.S. patent 5,514,578 and expands the coverage of U.S. 5,514,578 to include a broader range of ecdysone receptors from insect species other than Drosophila. The patents are based on the pioneering research of Dr. David Hogness, emeritus Munzer Professor of Developmental Biology and Biochemistry at Stanford University. RHeoGene holds an exclusive license to both patents for uses in cell-based assays, genomics, proteomics, gene therapy, cell culture/fermentation, transgenic animals and biosensors. The license does not cover uses in plants.

RHeoGene is the source for advanced applications, products, and technologies that manage gene expression. Seamlessly integrating biology and chemistry applications that deliver precise management of gene regulation, RHeoGene focuses on delivering customized inducible gene expression technology systems to advance drug discovery, functional genomics, proteomics, target validation, biotherapeutics production, and development of biosensors. RHeoGene's operations are located in Charlottesville, Va. and Spring House, Pa. For more information, visit
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 20, 2001
Previous Article:Malaysia's First Internet Service Provider Chooses iBasis As Exclusive Provider of Global VoIP Services.
Next Article:Gemin X Appoints Sanderling's Robert McNeil, Ph.D., as Chairman; Additional Directors Named To Board.

Related Articles
Plants under pressure: the touch that stunts.
Insect hormone inspires switch for genes.
Estrogen flips testosterone gene switch.
Gene Blues.
Pending Resolution: The Question of Who Owns DNA.
Insects on steroids.
Groomed DNA handles threats: mothering styles alter rats' stress responses.
Unlocking innovation: CEOs are learning how to better tap university R & D. The results could be powerful.
Response of the American lobster to the stress of shell disease.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters